New trials, publications, preprints and grants on this target, month by month.
Publication
Impact of nano-chitosan solution on psoriasis-like thin skin lesion induced by imiquimod in Wistar rats: Exploring novel epigenetic role targeting miR-155, JAK2/STAT3/RORC/IL-17A, and MyD88/NF-κB pathways.
4 Nov 2026· Histology and histopathology· PUBMED
Publication
Mechanism Investigation of Platycodon grandiflorum Active Ingredients in Regulating Epithelial-Mesenchymal Transition and Airway Remodeling in Asthma via Modulation of the Sirt6/RORγt/IL-17A Axis and IL-17A/MAPK Pathway.
3 Nov 2026· Journal of ethnopharmacology· PUBMED
Publication
Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors.
1 Nov 2026· Journal of drugs in dermatology : JDD· PUBMED
Publication
The role of IL-17A, PRKAA1, PSCA and MIR196A2 genes in gastric cancer susceptibility: a Systematic review and meta-analysis.
29 Oct 2026· Personalized medicine· PUBMED
Publication
MLN4924 prevents N4BP1 deficiency-driven IL-17 signaling autoactivation and psoriasiform dermatitis progression through blockade of Act1 nuclear localization.
27 Oct 2026· Inflammation research : official journal of the European Histamine Research Society ... [et al.]· PUBMED
Publication
Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ macrophages.
26 Oct 2026· Journal of hepatology· PUBMED
Publication
XuanBi Mitigates Rheumatoid Arthritis via Regulation of ECM-Receptor Interactions and IL-17 Signaling: Insights From Integrated Proteomic and Pharmacological Analyses.
25 Oct 2026· Food science & nutrition· PUBMED
Publication
Adult-onset chronic nonbacterial osteitis mimicking refractory axial psoriatic arthritis: successful treatment with combined IL-1/IL-17 inhibition: a case report and brief literature review.
23 Oct 2026· EULAR rheumatology open· PUBMED
Publication
Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database.
22 Oct 2026· Frontiers in pharmacology· PUBMED
Publication
Altered IL-23/IL-17A immune axis in Parkinson's disease: An exploratory analysis.
22 Oct 2026· Parkinsonism & related disorders· PUBMED
Publication
IL-17 Inhibitor-Associated New Onset Inflammatory Bowel Disease: Clinical Presentation and Management: A Report of Two Cases.
22 Oct 2026· ACG case reports journal· PUBMED
Publication
Inflammatory biomarkers (IL-6, IL-10, IL-17, TNF-α) in TB patients attending a tertiary care hospital in Bhubaneswar, Odisha: a cross - sectional study.
21 Oct 2026· Indian journal of medical microbiology· PUBMED
Publication
NBDP ameliorates metabolic-associated steatohepatitis by suppressing IL-17/STAT3 signaling and caspase-mediated apoptosis.
21 Oct 2026· Cellular signalling· PUBMED
Publication
An oral-origin Streptococcus salivarius associated with schizophrenia reshapes intestinal T-cell immunity and promotes IL-17A-dominated inflammation.
15 Oct 2026· Frontiers in immunology· PUBMED
Publication
Serum NF-κB p105 and IL-17 in psoriasis: associations with disease status and severity.
15 Oct 2026· Cutaneous and ocular toxicology· PUBMED
Publication
Changes in the FIB-4 index with IL-23 vs IL-17 inhibitors in psoriasis: a retrospective cohort study.
13 Oct 2026· Expert opinion on biological therapy· PUBMED
Publication
Comparative Effects of IL-17 and IL-23 Inhibitors on Lipid Profiles and Lipid-Derived Atherogenic Indices in Patients with Psoriasis.
13 Oct 2026· Pharmaceuticals (Basel, Switzerland)· PUBMED
Publication
Cordyceps Polysaccharides Attenuate Experimental Ischemic Stroke Injury: Association with IL-17/NF-κB Signaling.
12 Oct 2026· International journal of molecular sciences· PUBMED
Publication
Computational Identification of IL-17 a Small-Molecule Inhibitors as Potential Therapeutics for Plaque Psoriasis Through e-Pharmacophore Screening, Molecular Docking, and Molecular Dynamics Simulation.
12 Oct 2026· The protein journal· PUBMED
Publication
Impact of IL-17A and IL-23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis.
12 Oct 2026· Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG· PUBMED
Publication
IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy.
9 Oct 2026· Frontiers in immunology· PUBMED
Publication
Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates.
1 Oct 2026· Cureus· PUBMED
Publication
TNFα promotes brain-predominant EAE independent of IFNγ and IL-17A in HLA-DR3 transgenic mice.
1 Oct 2026· Journal of immunology (Baltimore, Md. : 1950)· PUBMED
Publication
Altered MAIT cell activation characteristics with impaired IL-10 and IL-17A response programs in active Crohn's disease.
1 Oct 2026· Journal of immunology (Baltimore, Md. : 1950)· PUBMED
Publication
A Case of Genital-Predominant Inverse Psoriasis With Psoriatic Arthritis Treated With Sequential IL-23/IL-17-Targeted Biologic Therapy.
30 Sept 2026· The Journal of dermatology· PUBMED
Publication
Peripheral HMGB1 Downregulation Is Associated With the S100-IL-17 Axis in Parkinson's Disease: An Integrated Bulk and Single-Cell Transcriptomic Analysis.
30 Sept 2026· Parkinson's disease· PUBMED
Publication
Targeting the PCSK9-PR-IL-17 axis for psoriasis therapy.
25 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Zhuche Pill alleviates DSS-induced colonic epithelial injury in mice: involvement of IL-17/NF-κB and Wnt/β-catenin signaling pathways.
24 Sept 2026· Journal of ethnopharmacology· PUBMED
Publication
Postmarketing reporting patterns of Candida-related events associated with bimekizumab and selective IL-17A inhibitors in psoriasis: a FAERS and JADER pharmacovigilance study.
22 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Environmental Exposure to Triclosan Promotes Rheumatoid Arthritis via KEAP1/NRF2 Inhibition and Subsequent IL-17 Signaling Activation.
22 Sept 2026· Environmental science & technology· PUBMED